NewcelX Ltd. (NCEL)
Nasdaq · Healthcare · Biotechnology
$2.86+0.35%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $16.5M
- P/E (trailing)
- 5.5
- 52-week range
- $1.83 – $19.30
- 52-week change
- −84.43%
- EPS (trailing)
- $0.52
Fiscal year to Dec 2025
- Net income
- −$8.3M
- Diluted EPS
- $2.16
- Free cash flow
- −$2.8M
From the company’s annual report on SEC EDGAR.
About NewcelX Ltd.
NewcelX Ltd., a biopharmaceutical company, engages in developing transformative stem-cell-derived therapies for Diabetes. The company develops NCEL-101, a cellular therapy product based on enriched pancreatic islet-like clusters for the treatment of Type 1 diabetes and Type 2 insulin dependent diabetes; AstroRx, an off-the-shelf cryopreserved cell therapy product for the treatment of Amyotrophic Lateral Sclerosis and neurodegenerative indications; and Dual Orexin-Receptor Agonist (DOXA), a small molecules platform for the treatment of sleep disorders, Neurodegenerative/ neuroinflammation diseases, and Diabetes Associated Neurological Disorders. It also develops iTOL-102, NCEL-201, NCEL-301, and NCEL-007. NewcelX Ltd. was founded in 2008 and is headquartered in Kloten, Switzerland.
Headquarters: Kloten, Switzerland · 9 employees · newcelx.com